| Abivax SA | SPONSORED ADS | $7.6M | 0.9% | 56,316 SH | New |
| Agios Pharmaceuticals Inc | Common | $35.5M | 4.1% | 1,303,373 SH | New |
| Alumis Inc | Common | $23.4M | 2.7% | 2,401,992 SH | New |
| Arcutis Biotherapeutics Inc | Common | $15.4M | 1.8% | 531,200 SH | New |
| Belite Bio Inc | SPONSORED ADS | $14.0M | 1.6% | 87,760 SH | New |
| Bright Minds Biosciences Inc | Common | $18.0M | 2.1% | 230,147 SH | New |
| Climb Bio Inc | Common | $10.7M | 1.2% | 2,671,480 SH | New |
| Context Therapeutics Inc | Common | $15.7M | 1.8%Prev: 2.3% | 10,679,391 SH | Increased-4,026,491 SH |
| Corvus Pharmaceuticals Inc | Common | $21.1M | 2.4% | 2,743,671 SH | New |
| Cullinan Therapeutics, Inc. | Common | $79.2M | 9.1%Prev: 7.4% | 7,648,268 SH | Increased |
| DBV Technologies S A | SPONSORED ADS | $19.1M | 2.2%Prev: 1.7% | 996,825 SH | Increased-57,679 SH |
| Dyne Therapeutics, Inc. | Common | $27.5M | 3.1%Prev: 3.0% | 1,405,388 SH | Increased-40,973 SH |
| Edgewise Therapeutics Inc | Common | $41.1M | 4.7%Prev: 4.6% | 1,655,256 SH | Increased-65,485 SH |
| enGene Holdings, Inc. | Common | $16.6M | 1.9% | 1,840,898 SH | New |
| Evommune Inc | Common | $1.9M | 0.2% | 113,022 SH | New |
| Liquidia Corp | Common | $48.3M | 5.5%Prev: 0.7% | 1,400,869 SH | Increased+1,200,869 SH |
| Madrigal Pharmaceuticals Inc | Common | $56.4M | 6.4%Prev: 7.5% | 96,780 SH | Increased-3,635 SH |
| Maze Therapeutics Inc | Common | $3.4M | 0.4% | 81,145 SH | New |
| Monte Rosa Therapeutics Inc | Common | $18.4M | 2.1% | 1,173,376 SH | New |
| Natera Inc | Common | $21.4M | 2.5%Prev: 2.6% | 93,551 SH | Increased-5,373 SH |
| Oric Pharmaceuticals Inc | Common | $14.7M | 1.7%Prev: 3.4% | 1,798,717 SH | Decreased+69,339 SH |
| Palvella Therapeutics Inc | Common | $21.5M | 2.5%Prev: 0.7% | 205,745 SH | Increased+138,322 SH |
| Protagonist Therapeutics Inc | Common | $17.4M | 2.0% | 199,471 SH | New |
| PTC Therapeutics Inc | Common | $32.7M | 3.7%Prev: 4.4% | 430,013 SH | Increased-8,464 SH |
| RAPT Therapeutics Inc | Common | $13.5M | 1.5% | 397,906 SH | New |
| Relay Therapeutics Inc. | Common | $18.9M | 2.2%Prev: 2.0% | 2,232,451 SH | Increased-50,229 SH |
| Revolution Medicines, Inc. | Common | $40.3M | 4.6%Prev: 2.4% | 505,672 SH | Increased+189,950 SH |
| Rocket Pharmaceuticals, Inc. | Common | $5.6M | 0.6%Prev: 2.1% | 1,586,076 SH | Decreased-2,317,305 SH |
| Sarepta Therapeutics Inc | Common | $1.5M | 0.2%Prev: 2.2% | 70,000 SH | Decreased-630,000 SH |
| Stoke Therapeutics Inc | Common | $24.4M | 2.8%Prev: 3.0% | 770,289 SH | Increased-19,409 SH |
| Syndax Pharmaceuticals Inc | Common | $28.1M | 3.2%Prev: 3.5% | 1,337,702 SH | Increased-37,972 SH |
| Tarsus Pharmaceuticals Inc | Common | $26.9M | 3.1%Prev: 3.3% | 328,869 SH | Increased-12,627 SH |
| Trevi Therapeutics Inc | Common | $41.2M | 4.7%Prev: 5.1% | 3,287,087 SH | Increased-119,868 SH |
| Uniqure NV | Common | $33.1M | 3.8% | 1,381,628 SH | New |
| Urogen Pharma Ltd | Common | $22.0M | 2.5%Prev: 0.4% | 941,378 SH | Increased+806,378 SH |
| Ventyx Biosciences Inc | Common | $14.8M | 1.7% | 1,639,061 SH | New |
| Werewolf Therapeutics, Inc. | Common | $884K | 0.1%Prev: 0.8% | 1,393,557 SH | Decreased-1,015,253 SH |
| Xenon Pharmaceuticals Inc | Common | $21.8M | 2.5%Prev: 3.3% | 485,620 SH | Increased-17,778 SH |